{"organizations": [], "uuid": "1b8da48cee114a2b6ad40abde05fe3409e624297", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180516.html", "section_title": "Archive News &amp; Video for Wednesday, 16 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-idorsia-starts-phase-3-registratio/brief-idorsia-starts-phase-3-registration-study-to-assess-lucerastat-as-potential-new-treatment-option-for-patients-with-fabry-disease-idUSASO0004UY", "country": "US", "domain_rank": 408, "title": "BRIEF-Idorsia Starts Phase 3 Registration Study To Assess Lucerastat As Potential New Treatment Option For Patients With Fabry Disease", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.364, "site_type": "news", "published": "2018-05-16T13:05:00.000+03:00", "replies_count": 0, "uuid": "1b8da48cee114a2b6ad40abde05fe3409e624297"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-idorsia-starts-phase-3-registratio/brief-idorsia-starts-phase-3-registration-study-to-assess-lucerastat-as-potential-new-treatment-option-for-patients-with-fabry-disease-idUSASO0004UY", "ord_in_thread": 0, "title": "BRIEF-Idorsia Starts Phase 3 Registration Study To Assess Lucerastat As Potential New Treatment Option For Patients With Fabry Disease", "locations": [], "entities": {"persons": [], "locations": [{"name": "idorsia", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 16 (Reuters) - IDORSIA LTD:\n* IDORSIA INITIATES MODIFY, A PHASE 3 REGISTRATION STUDY TO ASSESS LUCERASTAT AS A POTENTIAL NEW TREATMENT OPTION FOR PATIENTS WITH FABRY DISEASE Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-16T13:05:00.000+03:00", "crawled": "2018-05-17T14:29:14.023+03:00", "highlightTitle": ""}